.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
US Department of Justice
Fish and Richardson
Julphar
Moodys
Chubb
Cipla
Daiichi Sankyo
Johnson and Johnson
Healthtrust

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title:Low salt forms of polyallylamine
Abstract: Disclosed is a pharmaceutical composition comprising a stable polyallylamine hydrochloride polymer in which between about 4% to about 12% by weight of the polymer is a chloride anion and a pharmaceutically acceptable carrier or diluent.
Inventor(s): Petersen; John S. (Acton, MA), Burke; Steven K. (Sudbury, MA), Holmes-Farley; Stephen Randall (Arlington, MA)
Assignee: Genzyme Corporation (Cambridge, MA)
Filing Date:Apr 21, 2009
Application Number:12/427,127
Claims:1. A method of treating hyperphosphatemia in a patient in need thereof comprising administering to said patient a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a stable polyallylamine hydrochloride polymer wherein between about 4% to about 12% by weight of the polymer is chloride anion and between about 9.0% to about 27.0% of the amine groups in the polyallylamine polymer are protonated.

2. The method of claim 1, wherein between about 5% to about 9% by weight of the polymer is chloride anion.

3. The method of claim 2, wherein the polymer is a homopolymer.

4. The method of claim 3, wherein the polyallylamine hydrochloride polymer comprises a repeat unit represented by Structural Formula (I): ##STR00003##

5. The method of claim 4, wherein the polymer is crosslinked.

6. The method of claim 5, wherein the polymer is crosslinked with 2-hydroxypropyl crosslinking groups.

7. The method of claim 1, wherein said pharmaceutical composition is administered in a dosage of between about 0.5 grams/day to about 10 grams/day.

8. The method of claim 7, wherein said pharmaceutical composition is administered in a dosage of between about 0.5 grams/day to about 10 grams/day.

9. A method of treating hyperphosphatemia in a patient in need thereof comprising administering to said patient a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a stable polyallylamine homopolymer comprising repeat units represented by Structural Formula (I): ##STR00004## wherein the homopolymer is crosslinked with 2-hydroxypropyl groups, between about 9% and about 30% of the amine groups in the homopolymer are bonded to one of the 2-hydroxypropyl crosslinking groups, and between about 5% and about 9% by weight of the homopolymer is chloride anion and between about 9.0% to about 27.0% of the amine groups in the polyallylamine polymer are protonated.

10. The method of claim 9, wherein said pharmaceutical composition is administered in a dosage of between about 0.5 grams/day to about 10 grams/day.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Cipla
Queensland Health
AstraZeneca
Chinese Patent Office
Citi
Harvard Business School
US Army
Farmers Insurance
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot